Institution
German Red Cross
Healthcare•Berlin, Germany•
About: German Red Cross is a healthcare organization based out in Berlin, Germany. It is known for research contribution in the topics: Transplantation & Mesenchymal stem cell. The organization has 653 authors who have published 1146 publications receiving 40111 citations. The organization is also known as: Deutsches Rotes Kreuz & DRK.
Topics: Transplantation, Mesenchymal stem cell, Population, Stem cell, Antigen
Papers published on a yearly basis
Papers
More filters
••
TL;DR: This substudy compares three different bacterial detection systems in order to investigate the prevalence of bacterially contaminated pool platelet concentrates and apheresis platelets.
Abstract: Background and Objectives Since 2004, bacterial screening of platelets has been required in the USA and is also done on a voluntary basis in many European countries. The German Red Cross blood donor services conducted a prospective multicentre study in order to investigate the prevalence of bacterially contaminated pool platelet concentrates and apheresis platelet concentrates. This substudy compares three different bacterial detection systems.
Study Design and Methods Platelet concentrates were tested in parallel with BacT/ALERT, Scansystem‘ and Pall eBDS (n = 6307) in pool platelets. Apheresis platelets were tested in parallel with BacT/ALERT and Pall eBDS (n = 4730). All initially positive results were evaluated by a standardized procedure including evaluation by a microbiology reference laboratory.
Results One in 6307 pool platelets were confirmed positive by BacT/ALERT, whereas Pall eBDS and Scansystem failed to detect these samples. Only three samples were initially reactive with Pall eBDS without proof of any bacteria strains. The rate of false-positive results was substantially higher for BacT/ALERT (0·25%, 28 in 11 037 tested samples) than for eBDS (0·03%, 3 in 11 037 tested samples) or Scansystem (0·0%, 0 in 6307 tested samples). Three of 4730 apheresis platelets were confirmed positive by BacT/ALERT. These were negative with Pall eBDS.
Conclusion Sensitivity was best for BacT/ALERT, whereas specificity was enhanced for Pall eBDS and Scansystem. Scansystem required specially trained staff, whereas BacT/ALERT and Pall eBDS were easy, quick, user-friendly and objective methods.
44 citations
••
TL;DR: A formal process validation was performed to support submission of the protocol for CE release, a prerequisite for clinical use of Prodigy CD34+ products, and the automatic system is suitable for routine clinical application.
44 citations
••
44 citations
••
TL;DR: It is demonstrated for the first time that YKL-39 is expressed on TAMs, predominantly positive for stabilin-1, but not by malignant cells or other stromal cells in human breast cancer.
Abstract: In breast cancer, the tumor microenvironment plays a critical role in the tumor progression and responses to therapy. Tumor-associated macrophages (TAMs) are major innate immune cells in tumor microenvironment that regulate intratumoral immunity and angiogenesis by secretion of cytokines, growth factors as well as chitinase-like proteins (CLPs), that combine properties of cytokines and growth factors. YKL-39 is a chitinase-like protein found in human and absent in rodents, and its expression in TAMs and role in breast cancer progression was not studied to date. Here for the first time we demonstrate that YKL-39 is expressed on TAMs, predominantly positive for stabilin-1, but not by malignant cells or other stromal cells in human breast cancer. TGF-beta in combination with IL-4, but not IL-4 alone was responsible of the stimulation of the production of YKL-39 in human primary macrophages. Mechanistically, stabilin-1 directly interacted with YKL-39 and acted as sorting receptor for targeting YKL-39 into the secretory pathway. Functionally, purified YKL-39 acted as a strong chemotactic factor for primary human monocytes, and induced angiogenesis in vitro. Elevated levels of YKL-39 expression in tumors after neoadjuvant chemotherapy (NAC) were predictive for increased risk of distant metastasis and for poor response to NAC in patients with nonspecific invasive breast carcinoma. Our findings suggest YKL-39 as a novel therapeutic target, and blocking of its activity can be combined with NAC in order to reduce the risk of metastasis in breast cancer patients.
44 citations
••
TL;DR: The prevalence of bacterial contamination of random‐donor platelet concentrates is considerably lower than that of blood donations, and which key steps of the preparation procedure contribute to the elimination of bacteria was investigated.
44 citations
Authors
Showing all 658 results
Name | H-index | Papers | Citations |
---|---|---|---|
Johannes Oldenburg | 72 | 583 | 18790 |
Bodo Niggemann | 71 | 279 | 19475 |
Norbert Weissmann | 71 | 384 | 21187 |
Hubert Schrezenmeier | 69 | 360 | 16215 |
Triantafyllos Chavakis | 65 | 242 | 13247 |
Klaus Schwarz | 58 | 209 | 13407 |
Willy A. Flegel | 50 | 233 | 6742 |
Rainer M. Bohle | 49 | 235 | 6923 |
Torsten Tonn | 48 | 151 | 11328 |
Daniel Ricklin | 46 | 144 | 10713 |
Erhard Seifried | 44 | 254 | 7967 |
Pamela S. Becker | 42 | 257 | 6256 |
Karen Bieback | 41 | 135 | 10010 |
Halvard Bonig | 41 | 216 | 4828 |
Julia Kzhyshkowska | 40 | 126 | 5963 |